Skip to content
Krypton AI
Client portal
  1. 1Your company
  2. 2Pick a time

Book 30 minutes with us.

Start with your ticker. We prepare a first read on your company before we meet, and a person reviews it.

Prefer email? contact@kryptonai.io

Utah Medical Products Inc

Ticker
UTMD
Sector
Medical devices
Dated
Written 15 November 2026, published 16 November 2026
Stance
BUY (initiated)

Utah Medical lost its two largest customers but still earns a 31.0% operating margin and holds net cash worth 29.5% of its market value, with no debt.

Price (13 Nov 26)
$71.97
Price target (12m)
$106.60
Scenario value*
$100.51
Bear/Base/Bull
62.59/106.61/126.24
Market cap
$205.1M
Enterprise value
$144.6M
Free float
92.0% of S/O
Avg daily vol, 3m
33k / $2.3M
Short interest
5.8% float, -0.02pt since 30 Sep
Institutional own.
81.7%
Largest holder
Brandes Investment Partners, LP, 16.7%
Insider and board
8.0%

*Probability-weighted, 25/50/25, over 12 months. Price target is the base case, rounded to the nearest ten cents.

The thesis

  1. The customers behind the sales decline are already gone. Sales for the nine months to 30 September 2026 were $25.9M, down 12.2% from a year earlier. The two lost customers, PendoTECH and a China distributor of blood pressure kits, were 6.4% of FY2025 sales and bought nothing in 2026. So the comparison eases from here.
  2. Margins have held while sales fell. Nine-month gross margin was 57.5% and operating margin was 31.0%. Q3 gross margin slipped to 56.1% from 57.1% because the plant kept its staffing on lower shipments. The end of Femcare intangible amortization in Q1 2026 lifts operating income without changing cash.
  3. The balance sheet has no debt and net cash worth almost a third of the market value. Cash and investments were $85.2M at 30 September 2026, before the October tender offer. Pro forma cash is $60.5M, or $21.23 a share against a close of $71.97. Net cash is 29.5% of the $205.1M market capitalisation.
  4. The stock trades at a discount to every peer on the same measure. Enterprise value is $144.6M, or 11.7x operating income plus D&A for the twelve months to 30 September 2026, against a peer median of 18.4x. We apply that median to FY2027E and reach a price target of $106.60, which is 48.1% above the close.

The full report

6 pages, 513 KB, free with the LALC newsletter.

Utah Medical Products Inc

The full report is free with LALC, our research newsletter. Confirm your address from the email we send, and the report is on the page that opens. One click to leave.

Leave a comment

Comments are read before they appear.